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Abstract   
Currently, mercury has been identified as a risk factor of cardiovascular diseases among humans.  
Here, we have hypothesized that mercury modulates the activity of the endothelial lipid signaling 
enzyme phospholipase D (PLD), which is an important player in the endothelial cell (EC) barrier 
functions.  In order to test the hypothesis, monolayers of bovine pulmonary artery ECs 
(BPAECs) in culture, following labeling of membrane phospholipids with [32P], were exposed to 
mercuric chloride (inorganic form), methylmercury chloride (environmental), and thimerosal 
(pharmaceutical), and the formation of phosphatidylbutanol as an index of PLD activity was 
determined by thin-layer chromatography and liquid scintillation counting.  All three forms of 
mercury significantly activated PLD in BPAECs in a dose-dependent (0-50 µM) and time-
dependent (0-60 min) fashion.  Metal chelators significantly attenuated mercury-induced PLD 
activation in BPAECs, suggesting that cellular mercury-ligand interaction(s) is required for the 
enzyme activation and that chelators are suitable blockers for mercury-induced PLD activation in 
ECs.  Sulfhydryl (thiol-protective) agents and antioxidants also significantly attenuated the 
mercury-induced PLD activation in BPAECs, suggesting that the cellular thiols are probable 
targets for mercury action and that reactive oxygen species (ROS) play a role in mercury-induced 
PLD activation in ECs. Increases in ROS generation were observed in BPAECs following the 
exposure of cells to methylmercury that was attenuated by antioxidants; this confirmed the 
involvement of ROS/oxidative stress in the mercury-induced PLD activation in BPAECs.  For 
the first time, the results of this study revealed that mercury induced the activation of PLD in the 
vascular ECs wherein cellular thiols and ROS acted as signal mediators for the enzyme 
activation. The results suggest further that PLD signaling may play an important role in mercury-
induced endothelial dysfunctions and cardiovascular diseases. 
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Introduction 
Mercury (Hg) is a heavy metal belonging to the transition element series of the periodic table.  
The element has been in commercial (industrial) and medical uses for centuries (1) which results 
in  occupational exposures to mercury.  Although mercury occurs naturally in the environment, 
anthropogenic activities cause the release of the element into the environment leading to the 
pollution of air, water, and soil (1,2).  Coal and oil-fired power plants have been identified as the 
largest source of emission of mercury into the environment in the United States (4).  Inorganic 
mercury is toxic to many organisms and is converted to more toxic organic forms 
(methylmercury) through biomethylation by microorganisms (bacteria) (3).  Methylmercury 
reaches the organisms in the food chain and ultimately accumulates in humans, the top 
consumers (3).  Methylmercury toxicity to the experimental animals, poisoning and 
environmental toxicity to humans are well documented (5).  Dental amalgam fillings containing 
mercury have been in uncontrolled use in dental care worldwide(6).  Mercury leaching from the 
implanted dental amalgams has been attributed to mercury-induced adverse health effects in 
humans (6,7).  Mercury has also been recognized as a toxicant in occupational environments, 
contributing to work related disorders/diseases such as upper respiratory tract diseases, lung 
diseases, cardiovascular diseases, musculoskeletal disorders, and nervous system diseases among 
workers (10).  Overall, humans are exposed to all these forms of mercury through accidents, 
environmental pollution, food contamination, dental care, preventive medical practices, 
industrial and agricultural operations, and occupational operations (11,12). 
 Fish are contaminated with mercury in the form of methylmercury in the aquatic 
environment (12) and fish eaters are exposed to methylmercury.  Methylmercury has been a 
well-documented environmental teratogen in animals including humans (13).  Fish are also good 
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sources of omega-3 fatty acids, which have been shown to offer a multitude of heath benefits 
including better cardiovascular health among humans (13,16).  Consumption of fish has been 
shown as a major source of environmental mercury in humans that could lead to suppression of 
the beneficial effects of omega-3 fatty acids on the coronary artery disease (14,15). 
 The role of mercury toxicity as a possible risk factor in cardiovascular disease has been 
discussed (17).  Reports have been made on the toxic effects of metals in several diseases among 
humans including the vascular diseases (18).  The mercury levels in the toe nails of humans have 
been shown to be associated with the risk of myocardial infarction and high mercury levels have 
been attributed to the diminished cardioprotective effects of fish consumption among humans 
(19).  Therefore, elevated body levels of mercury, due to fish consumption by humans, have been 
hypothesized as a risk factor in coronary heart disease (20).  Increased levels of urinary mercury 
have been shown to be associated with elevated cholesterol levels in humans and mercury has 
been suggested as a risk factor of myocardial infarction, coronary disease, and cardiovascular 
disease (21).  An association between the occupational exposure to mercury in mining and 
refining and risk of cardiovascular diseases has been shown (22).  
 Although mercury has been shown to be associated with cardiovascular diseases among 
humans, detailed studies leading to the understanding of mechanisms of mercury-induced 
cardiovascular diseases are lacking at the current time.  Vascular endothelium plays a pivotal 
role in the structure and function of the blood vessel and maintains the homeostasis of the 
circulatory system and the entire body in general.  Methylmercury has been shown to cause 
hypertension in rats (23).  Mercury-induced vascular endothelial damage and vasculitis in 
humans upon autopsy have been documented (24).  Therefore, it is conceivable to hypothesize 
that mercury exerts its toxic effects on the vascular endothelium, which in turn may contribute to 
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the mercury-induced cardiovascular diseases.  Phospholipids of cellular membranes play an 
important role in the cell as the structural and functional entities.  Phospholipases are enzymes 
which specifically hydrolyze the membrane phospholipids and generate bioactive lipid second 
messengers, which play a vital role in cell signaling (25).  Phospholipase D (PLD) is one such 
signaling enzyme, ubiquitously present in all mammalian cells that preferentially hydrolyzes 
phosphatidylcholine (PC) generating phosphatidic acid (PA) and choline (26) (Schema-1).  PA is 
further metabolized to either 1,2-diacylglycerol (DAG) by phosphatidate phosphohydrolase or to 
lysophosphatidic acid (LPA) by phospholipase A1/A2 (26-28).  Agonist-mediated activation of 
PLD plays a pivotal role in signal transduction in mammalian cells (26,29-31).  Several 
functions, such as promotion of mitogenesis in fibroblasts, stimulation of oxidative bursts in 
neutrophils, increase of intracellular calcium, and activation of protein kinases and 
phospholipases have been attributed to the signaling actions of PA/LPA (26,29-31).  Two major 
forms of PLD, hPLD1 and hPLD2, have been cloned in mammalian cells; They are selectively 
activated by various cofactors such as Arf, Rho, Cdc42, detergents, and phosphatidylinositol 4,5-
biphosphate (PIP2) in cell-free preparations (32-38). 
 Therefore, we hypothesize that mercury activates PLD in the vascular endothelial cells 
(ECs), thus generating the bioactive signal lipid, PA, which may contribute to mercury-induced 
vascular disorders.  In order to test the current hypothesis, the well-established bovine pulmonary 
artery EC system (BPAECs) was chosen here as the EC model system.  Also in the present 
study, three different forms of mercury, mercuric chloride (inorganic form), methylmercury 
chloride (environmental form), and thimerosal (pharmaceutical form) were chosen and the 
activation of PLD in BPAECs in culture was studied following the treatment of cells with the 
mercury compounds.  In addition, the efficacy of chelator drugs in attenuating the mercury-
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induced PLD activation and the role of thiols and reactive oxygen species (ROS) in the mercury-
induced PLD activation was investigated.  For the first time, this study revealed that mercury as 
mercuric chloride, methylmercury chloride, and thimerosal representing the inorganic, 
environmental, and pharmacological forms of the element respectively, induced PLD activation 
in vascular ECs which was attenuated by heavy metal chelator agents and drugs, sulfhydryl 
group protectants, and antioxidants, suggesting that mercury-induced PLD activation in vascular 
ECs in culture was mediated by a mechanism involving cellular sulfhydryl groups (thiols) and 
intracellular ROS. 
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Materials and Methods 
    Materials. Bovine pulmonary artery endothelial cells (BPAECs) (passage 2) were 
purchased from Cell Applications Inc. (San Diego, CA).  Minimal essential medium (MEM), 
fetal bovine serum (FBS), trypsin, nonessential amino acids, DMEM phosphate-free medium, 
mercury chloride, methylmercury chloride, mercury acetate, mercury sulfate, thimerosal, propyl 
gallate, absorbic acid (vitamin C), catalase, ethylenediaminetetracetic acid (EDTA), 
pyrrollinedine dithiocarbamate (PDTC), D-penicillamine, dietyldithiocarbamic acid (DETC), 
dithiothreitol (DTT), N-acetyl-L-cysteine (NAC), and meso-2,3-dimercapto-succinic acid 
(DMSA) were obtained from Sigma Chemical Co. (St. Louis, MO).  MnTBAP was obtained 
from Calbiochem (San Diego, CA).  [32P]orthophospate was obtained from New England 
Nuclear (Wilmington, DE).  Phosphatidylbutanol (PBt) was purchased from Avanti Polar Lipids 
(Alabaster, AL).  DCFDA (6-carboxy-2’,7’-dichlorodihydroxyfluorescein diacetate dicarboxy 
methyl ester was purchased from Molecular Probes (Eugene, OR).  
    Cell culture.  BPAECs were cultured in MEM supplemented with 10% FBS, antibiotics, 
and growth as described previously (39).  Cells in culture were maintained at 37º C in a 
humidified environment of 5% CO2- 95% air and grown to contact-inhibited monolayers with 
typical cobblestone morphology.  When confluence was reached, cells were trypsinized and 
subcultured in T 75-cm2 flasks or 35 X 10-mm or 100-mm tissue culture dishes.  Confluent cells 
showed cobblestone morphology under light microscope and stained positive for Factor VIII.  
All experiments were conducted between 8 and 20 passages. 
PLD activation in ECs.  BPAECs in 35-mm dishes (5 X 105 cells/dish) were incubated 
with [32P]orthophosphate (5 µCi/ml) in phosphate-free DMEM containing 2% FBS for 18-25 h at 
37º C in 5% CO2 and 95% air (39).  The radioactive medium was removed by aspiration and 
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cells were incubated in serum-free MEM or MEM containing the selected forms of mercury 
(mercuric chloride or mercuric sulfate or mercuric acetate or methylmercury chloride or 
thimerosal) at the chosen µM concentrations in the presence of 0.05% butanol for specified 
lengths of time (0-60 min).  When required, cells prelabelled with [32P]orthophosphate were 
pretreated with selected pharmacological agents/inhibitors for 1 h and then exposed to mercury 
compound(s) in absence or presence of the pharmacological inhibitors and in the presence of 
0.05% butanol for specified lengths of time.  Incubations were terminated by the addition of 1 
mL of methanol:HCl (100:1 vol/vol) and lipids were extracted in chloroform:methanol (2:1 
vol/vol) (39). [32P]PBt formed as a result of PLD activation and concomitant 
transphysphatidylation reaction (an index of in vivo PLD activation) (Schema-2) was separated 
by thin-layer chromatography (TLC) with the upper phase of ethyl acetate: 2,2,4-trimethyl 
pentane: glacial acetic acid: water (65:10:15:50 by vol) as the developing solvent system.  
Unlabeled PBt was added as a carrier during TLC separation of lipids and was visualized upon 
exposure to iodine vapors. PBt spots were marked and scraped, and radioactivity-associated PBt 
was determined by liquid scintillation counting.  All values were normalized to 1 million dpm in 
total lipid extract and [32P]PBt formed was expressed as dpm/dish or percentage control. 
    ROS measurement by DCFDA fluorescence.  Formation of ROS in BPAECs in 35-mm 
dishes (5 X 105 cells/dish) was determined by DCFDA fluorescence in cells which were loaded 
with 10 µM DCDFA for 30 min in complete MEM at 37º C in a 95% air-5% CO2 environment 
prior to exposure to mercury compound(s) (40).  When required, cells preloaded with DCFDA 
were pretreated with the selected pharmacological agents/inhibitors for 1 h and then exposed to 
mercury compound(s) for specified lengths of time.  At the end of exposure to mercury 
compound(s) in the absence or the presence of pharmacological agents/inhibitors, the dishes 
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containing cells were placed on ice, cells were detached with a Teflon cell scraper, and the 
medium containing cell was transferred to 1.5-ml microcentrifuge tubes and centrifuged at 8,000 
g for 10 min at 4º C.  The supernatant medium was aspirated, and the cell pellet was washed 
twice with ice-cold PBS and sonicated on ice with a probe sonicator at a setting of 5 for 15 s in 
500 µl of ice-cold PBS to prepare cell lysates.  Fluorescence of oxidized DCFDA in cell lysates, 
an index of formation of ROS, was measured on a Gemini fluorescence plate reader with 
excitation and emission set at 490 and 530 nm, respectively, using appropriate blanks.  The 
extent of ROS formation was expressed as the arbitrary fluorescence units.  
Statistical analysis of data.  Standard deviation (SD) for each data point was calculated 
from triplicate samples.  Data were subjected to one-way analysis of variance, and pair wise 
multiple comparisons was done by Dunnett’s method with P<0.05, indicating significance. 
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Results 
Mercury activates PLD in a dose-dependent fashion. 
As no reports have been made so far on mercury-induced activation of PLD in animal cell 
systems including the vascular ECs, here, we investigated whether different forms of mercury 
(mercuric chloride, mercuric sulfate, mercuric acetate, thimerosal, and methylmercury chloride) 
would activate PLD in BPAECs in a dose dependent (0-50 µM) fashion following incubation of 
cells for 1 and 2 h with the chosen mercury compounds.  Mercuric chloride significantly caused 
10-, 13-, and 20-fold activation of PLD at 10, 25, and 50 µM concentrations upon treatment of 
cells for 1 h, respectively as compared to that in the cells treated with vehicle alone (Fig. 1A).  At 
2 h of incubation, although mercuric chloride caused a significant activation of PLD at 10 and 25 
µM concentrations similar to that observed at 1 h of treatment of cells with the same, the cell 
exhibited 25-fold increase in PLD activation upon exposure of cells to 50 µM of mercuric 
chloride as compared to that in the vehicle-treated cells (Fig. 1A).  BPAECs also showed similar 
extent of activation of PLD following exposure to mercuric sulfate.  Mercuric sulfate 
significantly caused 5-, 9-, and 12-fold increase in activation of PLD at 10, 25, and 50 µM doses, 
respectively upon treatment of cells for 1 h as compared to that in cells exposed to vehicle alone 
(Fig. 1B).  On the other hand, mercuric sulfate, only at 25 µM and 50 µM doses, significantly 
caused 9- and 8.5-fold activation of PLD in BPAECs following exposure of cells to the 
compound for 2 h as compared to that in cells treated with vehicle alone (Fig. 1B).  Both chloride 
and sulfate forms of mercury significantly caused a increase in the activation of PLD in BPAECs 
with increase in dose.  Mercury acetate significantly resulted in 4.5-, 7.5-, and 5-fold increases in 
PLD activation at 10, 25, and 50 µM doses of the compound respectively, following exposure of 
cells to 1 h treatment with the compound as compared to the same in the cells exposed to vehicle 
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alone (Fig. 1C).  BPAECs exhibited 2.5-, 7-, and 4-fold increases in PLD activation when 
exposed to 10, 25, and 50 µM mercury acetate respectively for 2 h as compared to the cells 
treated with vehicle alone (Fig. 1C).  Although mercury acetate resulted in a significant dose-
dependent increase with PLD activation in a linear fashion up to 25 µM concentrations of the 
agonist, at the 50 µM dose, the extent of mercury acetate-induced activation of the enzyme 
declined by approximately 3 orders of magnitude as compared to the same observed at 25 µM 
treatment of the same compound at 1 and 2 h (Fig. 1C).  However, mercury acetate caused a 
dose-dependent activation of PLD in BPAECs.  Thimerosal induced 2-, 6-, and 4-fold activation 
of PLD at 10, 25, and 50 µM doses respectively in BPAECs at 1 h of treatment of cells as 
compared to that in the vehicle-treated cells (Fig. 1D).  Thimerosal alone significantly causes 8-, 
13.5-, and 10.5-fold increases in PLD activity in cells at 10, 25, and 50 µM concentrations, 
respectively following 1 h exposure of cells to the compound as compared to the same in the 
vehicle-treated cells (Fig. 1D).  It was evident from this study that thimerosal resulted in 
significant and dose-dependent activation of PLD in BPAECs.  Methylmercury chloride at 10, 
25, and 50 µM doses caused a 3.5-, 2.5-, and 3- fold increase in PLD activity at 1h of treatment 
of cells with the compound respectively as compared to the same in cells treated with vehicle 
alone (Fig. 1E).  On the other hand, methylmercury chloride significantly resulted in 4.5- 2.5, 
and 3-fold increase in PLD activity in BPAECs at 10, 25, and 50 µM doses respectively, 
following exposure of cells to the compounds for 2 h as compared to the same in the cells 
exposed to vehicle alone (Fig. 1E).  The study also suggested that methylmercury chloride 
caused the maximum extent of activation at a concentration of 10 µM following exposure of 
cells for 1 and 2 h and upon further increasing the concentration of the agonist to 25 and 50 µM. 
Although methylmercury caused a significant increase in activation of PLD as compared to the 
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same in vehicle-treated cells, the extent of enzyme activation at those doses as compared to the 
same at 10 µM dose of methylmercury chloride was significantly lower and maintained a plateau 
(Fig. 1E).  Overall, these results revealed that the tested mercury compounds were effective in 
causing significant and dose-dependent activation of PLD in BPAECs. 
Mercury activates PLD in a time-dependent manner. 
Here, the time-dependent activation of PLD in BPAECs upon treatment with four different 
mercury compounds (mercuric chloride, mercuric sulfate, thimerosal, and methylmercury 
chloride) was studied.  As compared to the vehicle-treated cells, mercuric chloride (25 µM), even 
at 0 min of incubation caused a significant (9-fold) increase in PLD activation.  At 10 min of 
treatment, mercuric chloride caused a significant activation of PLD (20-fold) in cells, which 
declined slightly (15-fold) at 20 and 30 min of treatment with the agonist as compared to the 
same in cells exposed to the agonist for 0 min (Fig. 2A).  This study also revealed that cells 
exposed to mercuric chloride exhibited a plateau in the activation of PLD at 20 and 30 min of 
treatment.  Mercuric sulfate (25 µM) significantly caused 2.5-, 2.5-, and 5.5-fold increase in PLD 
activation in BPAECs at 15, 30, and 60 min respectively, as compared to the same in cells 
treated with mercuric sulfate for 0 min (Fig. 2B).  These results also revealed that mercuric 
sulfate induced a time-dependent and linear activation of PLD in ECs.  Thimerosal (25 µM) 
induced 8-, 13-, and 26-fold increase in PLD activation at 15, 30, and 60 min of treatment of 
cells respectively, as compared to the same in cells exposed to the agonist for 0 min, thus 
revealing a clear time-dependent and activation of the enzyme in BPAECs (Fig. 2C).  
Methylmercury chloride significantly caused 3-, 6-, and 6-fold activation of PLD in BPAECs at 
10, 20, and 30 min of treatment of cells as compared to the same in cells exposed to the agonist 
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for 0 min.  Collectively, these results revealed that all the four chosen forms of mercury caused a 
time-dependent activation of PLD in ECs. 
Metal chelating agents attenuate mercuric chloride induced PLD activation 
Chelating agents complex with transition metals and have been shown to protect against metal-
mediated adverse effects and metal toxicity (41).  Therefore, here, different chelating agents 
were included in this study in order to attenuate the mercuric chloride-induced PLD activation in 
BPAECs.  Prior to exposure of cells to mercuric chloride (25 µM) for 30 min, cells were 
pretreated for 1 h with basal MEM or MEM containing the selected chelating agent and then 
incubated with mercuric chloride in presence of the chelating agent for 30 min.  The classic trace 
element chelating agent, EDTA, significantly attenuated the mercury chloride-induced PLD 
activation in BPAECs (30% and 80% inhibition at 1 and 5 mM of EDTA treatment, respectively) 
(Fig. 3A).  One of the thiocarbamate derivatives, a widely used heavy-metal chelating agent, 
DETC offered significant and dose dependent attenuation of mercury chloride-induced activation 
of PLD in BPAECs (20%, 40%, and 60% attenuation at 100 µM, 500 µM, and 1 mM of DETC 
treatment, respectively) (Fig. 3B).  Another well-known thiocarbamate chelating agent, PDTC 
also significantly attenuated the mercuric chloride induced PLD activation in BPAECs (50%, 
55%, and 60% attenuation at 100 µM, 500 µM, and 1 mM of PDTC treatment, respectively) in a 
dose-dependent fashion (Fig. 3C).  The results revealed that EDTA was the most effective 
chelating agent in causing almost complete inhibition of the mercuric chloride induced activation 
in BPAECs followed by the thiocarbamate class of chelating agents. 
Antioxidants and sulfhydryl agents attenuate mercuric chloride-induced PLD activation. 
Heavy metals including mercury have been shown to cause oxidative stress which in turn has 
been shown to activate PLD in different cellular systems including vascular ECs (39,42).  Also, 
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it has been reported that the thiols (non-protein and protein) are the targets for heavy metal 
cellular actions (41,42).  Altered thiol redox has been shown to activate PLD in ECs (41,42).  
Therefore, in order to establish the role of oxidative stress (ROS) and thiol alterations in 
mercuric chloride-induced PLD activation in BPAECs, here the effects of well established 
antioxidants (vitamin C, propyl gallate, catalase, and NAC) and thiol (sulfhydryl) protective 
agents (DMSA, NAC, DTT, and D-penicillamine) were investigated on the mercuric chloride-
induced PLD activation in BPAECs.  Prior to treatment of cells with mercuric chloride (25 µM) 
for 30 min, cells were pretreated for 1 h with basal MEM or MEM containing the chosen 
antioxidants or thiol protective agents and then incubated with mercuric chloride in presence of 
the antioxidants or thiol protective agents for 30 min.  Vitamin C, even at a dose of 100 µM, 
significantly attenuated the mercuric chloride-induced activation of PLD in BPAECs (50% 
decrease) and upon further increasing the concentration of vitamin C to 500 µM and 1 mM 
caused further significant attenuation (56% and 67% decrease) of the mercuric chloride-induced 
PLD activation in cells (Fig. 4A). Although catalase failed to inhibit the mercuric chloride-
induced PLD activation in BPAECs, propyl gallate (100 µM) caused significant attenuation 
(67% decrease) of mercuric chloride-induced PLD activation (Fig. 4B).  All the tested thiol 
protective agents (DMSA 1 mM, NAC 500 µM, DTT 500 µM, and D-penicillamine 500 µM) 
were the most effective agents in causing significant inhibition of mercuric chloride-induced 
PLD activation in BPAECs.  DMSA, NAC, DTT, and D-Penicillamine caused 95%, 73%, 86%, 
and 90% inhibition of mercuric chloride induced PLD activation, respectively in ECs (Fig. 4B 
and 4C). 
Metal chelating agents and antioxidants attenuate methylmercury chloride-induced PLD 
activation.  The earlier experiments of this study revealed that the PLD activation in BPAECs 
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induced by the inorganic form of mercury, mercury chloride, was attenuated by the heavy metal 
chelating agents.  Therefore, here, the effects of well established chelating agents including 
EDTA (1 mM), PDTC (1 mM), DETC (1 mM) and D-penicillamine (1-10 µM) were examined 
on the methylmercury chloride-induced PLD activation in BPAECs.  Prior to treatment of cells 
with methylmercury chloride (10 µM) for 30 min, cells were pretreated for 1 h with basal MEM 
or MEM containing the chosen chelating agents and then exposed to methylmercury chloride in 
presence of the chelating agents for 30 min.  Although EDTA caused a 9% inhibition of 
methylmercury chloride-induced PLD activation in BPAECs, the extent of enzyme inhibition 
was not statistically significant (Fig. 5A).  However, the thiocarbamate chelating agents, PDTC 
and DETC, significantly caused 27% and 55% of attenuation of the methylmercury chloride-
induced activation of PLD in BPAECs, respectively (Fig. 5B).  The widely used heavy-metal 
chelator drug, D-penicillamine (1 and 5 µM), significantly caused 30% inhibition of the 
methylmercury chloride-induced PLD activation and upon increasing the concentration of D-
penicillamine to 10 µM, the extent of inhibition of methylmercury chloride-induced PLD 
activation was 50% and significant (Fig. 5C).  These results showed that the metal chelating 
agents offered up to 50% inhibition of methylmercury chloride-induced PLD activation in 
BPAECs, as opposed to attenuating 60-80% of the mercuric chloride-induced PLD activation in 
BPAECs. 
Antioxidants and sulfhydryl agents attenuate methylmercury chloride-induced PLD activation.  
As the earlier results of this study revealed that mercuric chloride-induced PLD activation in ECs 
was significantly attenuated by antioxidants, here, the effects of antioxidants on the 
methylmercury chloride-induced PLD activation in BPAECs were investigated.  Prior to 
challenging the cells with methylmercury chloride (10 µM) for 30 min, BPAECs were pretreated 
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for 1 h with antioxidants (NAC 1 mM; propyl gallate 50, 100, and 500 µM; vitamin C 1 mM; 
catalase 50 µg/mL; MnTBAP 20 µM, DTT 500 µM, and DMSA 1 mM), and then treated with 
methylmercury chloride for 30 min.  NAC, a thiol antioxidant, significantly and almost 
completely (80% inhibition) attenuated the methylmercury chloride-induced PLD activation in 
BPAECs (Fig. 5A).  Propyl gallate, the well-known phenolic antioxidant, significantly attenuated 
the methylmercury-induced PLD activation in a dose-dependent fashion in BPAECs (19%, 29%, 
and 30% decrease at 50, 100, and 500 µM doses of propyl gallate, respectively) (Fig. 5D).  
However, in comparison with the mercuric chloride-induced PLD activation in ECs that was 
attenuated by vitamin C, methylmercury chloride-induced PLD activation in BPAECs was not 
inhibited by vitamin C but was significantly enhanced by the vitamin (Fig. 6A).  On the other 
hand, catalase, significantly attenuated methylmercury chloride-induced PLD activation in 
BPAECs (18% decrease) (Fig. 6A).  MnTBAP, a superoxide dismutase mimetic, failed to 
attenuate but significantly enhanced the methylmercury-induced PLD activation in BPAECs 
(Fig. 6B).  Sulfhydryl protective agents (thiols), DTT and DMSA, significantly and almost 
completely attenuated the methylmercury chloride-induced PLD activation in BPAECs (90% and 
92% decrease at 500 µM DTT and 1 mM DMSA, respectively) (Fig. 6B).  These results 
suggested that some selective antioxidants and all the tested sulfhydryl (thiol) protective agents 
significantly attenuated the methylmercury chloride-induced PLD activation in BPAECs. 
Metal chelating agents and redox-active antioxidants attenuate thimerosal-induced PLD 
activation.  As the earlier results of this study showed that metal chelating agents and 
antioxidants caused attenuation of mercuric chloride- and methylmercury chloride-induced PLD 
activation in BPAECs, here, the effects of metal chelating agents and redox-active antioxidants 
on the thimerosal-induced PLD activation in BPAECs were investigated.  Prior to treatment of 
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cells with thimerosal (25 µM) for 30 min, BPAECs were pretreated with EDTA (1 mM), NAC (1 
mM), PDTC (1 mM), D-penicillamine (1 mM), vitamin C (1 mM), DMSA (1 mM), and (DETC 
1 mM) for 1 h and then treated with thimerosal for 30 min in presence of the metal chelating 
agents and antioxidants.  EDTA caused significant attenuation (30% decrease) of the thimerosal-
induced PLD activation in BPAECs (Fig. 7A). The two well established metal chelating agents, 
PDTC and D-penicillamine, significantly attenuated the thimerosal-induced PLD activation in 
BPAEC (30% and 65% decrease, respectively) (Fig. 7B).  DETC, the other thiocarbamate 
chelating agent, also was effective in causing significant attenuation (40% decrease) of the 
thimerosal induced PLD activation in BPAEC (Fig. 8A).  NAC, the well-established sulfhydryl 
(thiol) group protector and thiol antioxidant, significantly and completely (96% decrease) 
attenuated the thimerosal-induced PLD activation in BPAECs (Fig. 7A).  Vitamin-C, the well 
characterized redox active antioxidant, significantly attenuated (35% decrease) the thimerosal 
induced PLD activation in cells.  These results revealed that the metal chelating agents and redox 
active antioxidants caused significant inhibition of thimerosal-induced PLD activation in 
BPAECs. 
Antioxidants and sulfhydryl agents attenuate thimerosal-induced PLD activation.  The earlier 
results of this study showed that certain selected antioxidants and sulfhydryl (thiol) agents 
attenuated PLD activation induced by mercuric chloride and methylmercury chloride.  Therefore, 
here, the effects of the antioxidants and sulfhydryl agents on the thimerosal-induced PLD 
activation in BPAECs were investigated.  Prior to treatment of cells with thimerosal (25 µM) for 
30 min, BPAECs were pretreated with NAC (1 mM), catalase (50 µg/mL), DTT (500 µM), 
MnTBAP (20 µM), DMSA (1 mM), and propyl gallate (100 µM) for 1 h, and then exposed to 
thimerosal for 30 min.  Catalase failed to attenuate thimerosal-induced PLD activation (Fig. 8A) 
 21
whereas both MnTBAP and propyl gallate significantly attenuated (30% and 10% decrease at 
MnTBAP 20 µM and propyl gallate 100 µM, respectively) the thimerosal-induced PLD 
activation in BPAECs (Fig. 8B).  All the three chosen sulfhydryl agents, NAC, DMSA, and DTT 
significantly and almost completely attenuate the thimerosal-induced PLD activation in BPAECs 
(96%, 83%, and 80% decrease at NAC 1 mM, DMSA 1 mM, and DTT  500 µM, respectively) 
(Figs. 7A, 7C, and 8A).  Collectively, these results revealed that antioxidants and sulfhydryl 
(thiol protective) agents also significantly attenuated the thimerosal-induced PLD activation in 
BPAECs. 
Methylmercury chloride induces ROS generation in a dose dependent fashion. 
As antioxidants attenuated PLD activation in BPAECs induced by mercury (mercuric chloride, 
methylmercury chloride, and thimerosal), it was hypothesized here that all three chosen forms of 
mercury in this study would induce ROS generation in ECs.  In order to test the hypothesis, 
BPAECs were treated with different concentrations (0-15 µM) of mercuric chloride, 
methylmercury chloride, and thimerosal for 30 min and the subsequent formation of intracellular 
ROS was determined.  Of all the three mercury compounds, methylmercury chloride was the 
only mercury species which induced detectable levels of ROS in BPAECs as analyzed by the 
DCFDA fluorescence ROS assay.  Methylmercury chloride markedly induced intracellular ROS 
formation (4.5-fold and 6.6-fold at 10 and 15 µM concentrations) as compared to that in the 
vehicle-treated cells (Fig. 9A). These results showed that methylmercury chloride was effective 
in inducing generation of ROS in BPAECs.  
Antioxidants attenuate methylmercury chloride-induced ROS generation. 
Our previous results showed that methylmercury chloride induced intracellular ROS generation 
in BPAECs in a dose-dependent fashion.  Therefore, here, we investigated the effects of 
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antioxidants on the methylmercury chloride-induced intracellular ROS generation in ECs.  Prior 
to challenging the BPAEC with methylmercury chloride (10 µM) for 30 min, cells were 
pretreated with two well-established antioxidants (NAC 10 mM and MnTBAP 10 µM) for 2 h 
and then treated with methylmercury chloride (10 µM) for 30 min.  NAC markedly attenuated 
the methylmercury chloride-induced intracellular ROS generation (70%) to the extent exhibited 
by the cells treated with vehicle alone (Fig. 9B).  However, the superoxide dismutase mimetic, 
MnTBAP, was only effective to cause a partial (30% decrease) attenuation of the methylmercury 
chloride-induced intracellular ROS generation in BPAECs (Fig. 9C).  Overall, NAC appeared to 
be the most efficient antioxidant in causing a marked attenuation of methylmercury chloride-
induced intracellular ROS formation in BPAECs. 
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Discussion 
 The results of the present study revealed that mercury as mercuric chloride (inorganic 
form), methylmercury chloride (environmental organic form), and thimerosal (pharmaceutical 
organic form) induced the activation of PLD in vascular ECs in culture.  This is the first 
observation showing the heavy-metal-induced activation of PLD in a biological system.  The 
study also showed that metal chelators, sulfhydryl protective agents, and antioxidants attenuated 
the mercury-induced activation of PLD in ECs.  The observation in this study that 
methylmercury chloride induced the generation of ROS in ECs suggested the involvement of 
ROS/oxidative stress in the methylmercury chloride-induced PLD activation in ECs.  
Collectively, the results of the current study showed for the first time that mercury induced the 
activation of PLD in BPAECs involving the cellular thiols and ROS upstream of activation of the 
enzyme (Scheme-3). 
 Several agonists such as hormones, growth factors, neurotransmitters, cytokines, and 
ROS have been shown to activate PLD in different mammalian cells and tissues through agonist-
specific and cell-specific signaling mechanisms of regulation (39).  Oxidant (ROS)-induced 
activation of PLD in many cell systems including ECs has been shown to be regulated by PKC, 
mitogen-activated protein kinases, and tyrosine kinases (39,43,44).  Redox regulation of PLD in 
ECs involving the thiol-redox system has been documented (45).  The results of the current study 
clearly showed that sulfhydryl protectants and antioxidants attenuated the mercury-induced PLD 
activation in BPAECs, further suggesting the oxidant and thiol regulation of mercury-induced 
PLD activation in ECs.  Mercury toxicity has been shown to be associated with metal-induced 
oxidative stress involving lipid peroxidation and protein oxidation (42).  Depletion of GSH and 
binding of the metal to protein thiols have been linked to heavy metal toxicity (42).  Several 
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studies have also shown that methylmercury induces oxidative stress in cellular systems leading 
to cytotoxicity (46).  The results of the current study are also in agreement with the earlier 
reports that methylmercury-induced generation of ROS in BPAECs.  Together, the observations 
that mercury induced the generation of ROS and antioxidants and sulfhydryl agents attenuated 
the mercury-induced activation of PLD in BPAECs confirmed that oxidative stress and 
alterations in cellular thiols played a significant role in the mercury-induced activation of PLD in 
ECs.  Reports made earlier showing that oxidants and thiol redox alterations activate PLD in ECs 
support the findings of the current study along these lines (43).  This is further supported by the 
observation in the current study that mercuric chloride induced the loss of cellular GSH in 
BPAECs (data not shown).  However, the upstream regulation of mercury-induced PLD 
activation in BPAECs by PKC, MAPKs, and tyrosine kinases is not ruled out as oxidative stress 
and thiol redox alterations have been shown earlier to modulate PLD activation in different 
cellular systems through the kinase signaling cascades (43-45).  This further warrants a detailed 
investigation. 
 Metal chelators have been used widely as drugs in treating heavy metal poisoning and 
toxicity in cellular systems, laboratory animal models, and humans in clinical settings (41).  
Complexation of heavy metals by proteins at the histidine and cysteine (-SH) residues has been 
recognized as one of the primary mechanisms of heavy metal toxicity.  PLD is an enzyme with 
histidine in the active site (38) and it is conceivable that mercury may directly bind to this 
residue thus leading to its activation.  Alternatively, sulfhydryl groups (GSH and protein thiols) 
can be good candidates to react with mercury in the cell for metal-ligand complex formation and 
may cause conformational changes in PLD, leading to the activation of the enzyme.  
Nevertheless, upstream signaling kinases and other associated proteins which are rich in metal-
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binding residues (-SH and histidine) can also form coordination complexes with mercury, 
undergo activation, and subsequently modulate the activity of PLD in ECs.  Needless to say, the 
findings of this study on the attenuation of mercury-induced PLD activation by certain metal 
chelators indicated the arrest of possible complexation of mercury with the protein targets in 
BPAECs and thus assured the possible use of those chelators in alleviating the adverse effects of 
mercury at the cellular level such as the activation of membrane phospholipid hydrolyzing PLD 
which can also lead to changes in membrane fluidity and disruption in the bilayer. 
 The physiological significance of agonist-induced PLD activation in modulating EC 
function is emerging (43).  Exogenous administration of PA (the bioactive lipid signal mediator 
generated by PLD) has been shown to increase albumin paracellular flux across EC monolayers 
in culture (43,48).  Currently, the mechanisms by which PA regulates EC barrier function are not 
clearly understood and warrant further study.  Based on the results of the current study that 
mercury induced the activation of PLD in BPACEs, it is surmised here that mercury through 
PLD-generated PA formation, may cause EC barrier dysfunction. 
 In conclusion, the results of this study showed for the first time that mercury induced the 
activation of PLD in ECs further suggesting the role of PLD-generated bioactive lipid signal 
mediators in the toxicity of mercury to vascular endothelium and blood vessel and also mercury-
associated cardiovascular diseases. 
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Figure Legends 
Figure 1:  Mercury activates PLD in a dose-dependent fashion. 
BPAECs (5 X 105 cells/35-mm dish) were labeled with [32P]orthophosphate in DMEM 
phosphate-free medium for 12 h.  Following [32P]orthophosphate labeling, cells were treated 
with different concentrations (0-50 µM) of mercuric chloride (A), mercuric sulfate (B), mercuric 
acetate (C), thimerosal (D), and methylmercury chloride (E) for 1 and 2 h in MEM containing 
0.05% butanol.  At the end of incubation [32P]PBt formed was determined as described under 
Materials and Methods.  Data represent means + S.D. of three independent experiments. 
*Significantly different at P<0.05 as compared to cells not treated with the mercury 
compound(s). 
Figure 2:  Mercury activates PLD in a time-dependent manner. 
BPAECs (5 X 105 cells/35-mm dish) were labeled with [32P]orthophosphate in DMEM 
phosphate-free medium for 12 h.  Following [32P]orthophosphate labeling, cells were treated 
with MEM alone or MEM containing mercuric chloride (25 µM) (A) or mercuric sulfate (25 
µM) (B) or thimerosal (25 µM) (C) or methylmercury chloride (10 µM) (D) for 0-60 min in 
presence of 0.05% butanol.  At the end of incubation, [32P]PBt formed was determined as 
described under Materials and Methods.  Data represent means + S.D. of three independent 
experiments. *Significantly different at P<0.05 as compared to cells not treated with the mercury 
compound(s). 
Figure 3:  Metal chelating agents attenuate mercuric chloride-induced PLD activation. 
BPAECs (5 X 105 cells/35-mm dish) were labeled with [32P]orthophosphate in DMEM 
phosphate-free medium for 12 h.  Following [32P]orthophosphate labeling, cells were pretreated 
for 1 h with MEM or MEM containing EDTA (1 and 5 mM; A) or DETC (100 µM, 500 µM, 
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1mM; B) or PDTC (100 µM, 500 µM, and 1 mM; C) and then subjected to treatment with 
vehicle or mercuric chloride (25 µM) for 30 min in presence of 0.05% butanol.  At the end of 
incubation, [32P]PBt formed was determined as described under Materials and Methods.  Data 
represent means + S.D. of three independent experiments. *Significantly different at P<0.05 as 
compared to cells treated with vehicle alone.  ** Significantly different at P<0.05 as compared to 
cells treated with mercuric chloride alone. 
Figure 4:  Antioxidants and sulfhydryl agents attenuate mercuric chloride-induced PLD 
activation. 
BPAECs (5 X 105 cells/35-mm dish) were labeled with [32P]orthophosphate in DMEM 
phosphate-free medium for 12 h.  Following [32P]orthophosphate labeling, cells were pretreated 
for 1 h with MEM alone or MEM containing Vitamin C (100 µM, 500 µM, and 1 mM; A) or 
antioxidants (propyl gallate 100 µM, Catalase 50 µg/mL, and DMSA 1mM; B) or sulfhydryl 
agents (NAC, DTT, and D-penicillamine 500 µM; C) and then treated with mercuric chloride 
(25 µM) for 30 min in presence of 0.05% butanol.  At the end of incubation, [32P]PBt formed 
was determined as described under Materials and Methods.  Data represent means + S.D. of three 
independent experiments. *Significantly different at P<0.05 as compared to cells treated with 
vehicle alone.  ** Significantly different at P<0.05 as compared to cells treated with mercuric 
chloride alone. 
Figure 5:  Metal Chelating agents and antioxidants attenuate methylmercury chloride-induced 
PLD activation.  
BPAECs (5 X 105 cells/35-mm dish) were labeled with [32P]orthophosphate in DMEM 
phosphate-free medium for 12 h.  Following [32P]orthophosphate labeling, cells were pretreated 
for 1 h with MEM alone or MEM containing EDTA (1 mM) and NAC (1 mM) (A) or PDTC (1 
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mM) and DETC (1 mM) (B) or D-penicillamine (1, 5, and 10 µM) (C) or propyl gallate (50, 100, 
and 500 µM) (D) and treated with methylmercury chloride (10 µM) for 30 min in presence of 
0.05% butanol.  At the end of incubation, [32P]PBt formed was determined as described under 
Materials and Methods.  Data represent means + S.D. of three independent experiments. 
*Significantly different at P<0.05 as compared to cells treated with vehicle alone.  ** 
Significantly different at P<0.05 as compared to cells treated with methylmercury chloride alone. 
Figure 6:  Antioxidants and sulfhydryl agents attenuate methylmercury chloride-induced PLD 
activation.   
BPAECs (5 X 105 cells/35-mm dish) were labeled with [32P]orthophosphate in DMEM 
phosphate-free medium for 12 h.  Following [32P]orthophosphate labeling, cells were pretreated 
for 1 h with MEM alone or MEM containing Vitamin C (1mM) and catalase (1 µg/µL) (A) or 
MnTBAP (20 µM), DTT (500 µM), DMSA (1 mM) (B) and then treated with methylmercury 
chloride (10 µM) for 30 minutes in presence of 0.05% butanol.  At the end of incubation, 
[32P]PBt formed was determined as described under Materials and Methods.  Data represent 
means + S.D. of three independent experiments. *Significantly different at P<0.05 as compared 
to cells treated with vehicle alone.  ** Significantly different at P<0.05 as compared to cells 
treated with methylmercury chloride alone. 
Figure 7:  Metal chelating agents and redox-active antioxidants attenuate thimerosal-induced 
PLD activation. 
BPAECs (5 X 105 cells/35-mm dish) were labeled with [32P]orthophosphate in DMEM 
phosphate-free medium for 12 h.  Following [32P]orthophosphate labeling, cells were pretreated 
for 1 h with MEM alone or MEM containing EDTA (1 mM) and NAC (1 mM) (A) or PDTC (1 
mM) and D-penicillamine (1 mM) (B) or vitamin c (1 mM) and DMSA (1 mM) (C) and then 
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treated with thimerosal (25 µM) for 30 min in presence of 0.05% butanol.  At the end of 
incubation, [32P]PBt formed was determined as described under Materials and Methods.  Data 
represent means + S.D. of three independent experiments. *Significantly different at P<0.05 as 
compared to cells treated with vehicle alone.  ** Significantly different at P<0.05 as compared to 
cells treated with thimerosal alone. 
Figure 8:  Antioxidants and sulfhydryl agents attenuate thimerosal-induced PLD activation. 
BPAECs (5 X 105 cells/35-mm dish) were labeled with [32P]orthophosphate in DMEM 
phosphate-free medium for 12 h.  Following [32P]orthophosphate labeling, cells were pretreated 
for 1 h with MEM alone or MEM containing catalase (50 µg/µL), DTT (500 µM), and DETC (1 
mM) (A) or MnTBAP (20 µM) and propyl gallate (100 µM) (B) and then treated with thimerosal 
(25 µM) for 30 min in presence of 0.05% butanol.  At the end of incubation, [32P]PBt formed 
was determined as described under Materials and Methods.  Data represent means + S.D. of three 
independent experiments. *Significantly different at P<0.05 as compared to cells treated with 
vehicle alone.  ** Significantly different at P<0.05 as compared to cells treated with thimerosal 
alone. 
Figure 9:  Methylmercury chloride induces ROS generation in BPAECs: Attenuation by 
antioxidants 
BPAECs (5 X 105 cells/35-mm dish) were treated with basal MEM or MEM containing 
increasing concentrations of methylmercury chloride (0-15 µM) and incubated for 30 min (A).  
To investigate the effects of antioxidants, BPAECs (5 X 105 cells/35-mm dish) were treated for 1 
h with basal MEM or MEM containing NAC (10 mM) (B) or MnTBAP (10 µM) (C) and then 
treated with methylmercury chloride for 30 min in presence of antioxidants.  At the end of 
incubation, intracellular formation of ROS was determined by measuring DCFDA fluorescence 
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as described in Materials and Methods.  Data represent means + S.D. of three independent 
experiments. 
Schema-1:  Agonist-induced phospholipase A2 (PLA2) and phospholipase D (PLD) activation 
in cells and generation of lipid-derived second messengers and action of different phospholipases 
on membrane phospholipid. 
Schema-2:  PLD-mediated hydrolysis of membrane phosphatidylcholine (PC) and generation of 
phosphatidic acid (PA), diacylglycerol (DAG), and lysophosophatidic acid (LPA). 
Transphoshpatidylation of the PLD-mediated PA to phosphatidylalcohol is a characteristic 
feature of the enzyme which is exploited for the assay of the activity of PLD in biological 
systems. 
Schema-3:  Mechanism of mercury-induced activation of PLD in ECs. 
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